VistaGen Says Data From Late-Stage Anxiety Study ‘Not Consistent’ With Prior Positive Phase 2 Study
VistaGen Therapeutics Inc (NASDAQ:VTGN) has announced topline results from its PALISADE-1 Phase 3 trial of PH94B for the acute treatment of…
iRhythm Gains FDA Clearance For Its Clinically Integrated ZEUS System
iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced it received FDA 510(k) clearance for its ZEUS (Zio ECG Utilization
Snap Analyst Downgrades Stock, Says Earlier Thesis On Shares Posting Gains ‘Compromised’
Snap stock lost over one-quarter of its market cap in Thursday’s after-hours trading following the disappointing quarterly results reported by the Snapchat parent.
American Express Shares Shine as Travel, Entertainment Rebound, Sees Higher FY22 Sales
American Express Company (NYSE:AXP) has reported a Q2 net income of $2.0 billion, or $2.57 per share, down from $2.3…
AC Immune Announces Upcoming Presentations at the Alzheimer’s Association International Conference Jul. 31-Aug. 4
New data from the API ADAD Study to be presented in AAIC Focused Topic Session
New Phase 2 results from investigator-sponsored trial of the Tau PET tracer PI-2620 in Alzheimer's
Bavarian Nordic’s Monkeypox Vaccine Gets Thumbs Up From EU Regulator
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a “positive opinion” recommending Bavarian Nordic…
Snap’s ‘Ugly’ Results A Forewarning For Meta Investors? Munster Throws Light On Q2 Results
Snap, Inc. (NYSE: SNAP) reported disappointing second-quarter results Thursday and refrained from giving guidance for the running quarter.
Autoliv Q2 Earnings Top Estimates
Autoliv Inc (NYSE:ALV) reported second-quarter FY22 sales growth of 2.9% year-on-year, to $2.08 billion, beating the consensus of $2.05 billion. Operating…
Once A Cancer Company Silverback Merges With Small Biotech Working On Allergy Treatment
ARS Pharmaceuticals Inc will merge with Silverback Therapeutics Inc (NASDAQ:SBTX) in an all-stock transaction, with a new entity operating under the…
Liminal BioSciences Pulls Plug On Its Lead Development Program
Liminal BioSciences Inc (NASDAQ:LMNL) will discontinue the development of fezagepras based on results from the Phase 1a single ascending dose (SAD)…